Published in Am J Med Sci on September 01, 2008
Time course of Graves' orbitopathy after total thyroidectomy and radioiodine therapy for thyroid cancer. Medicine (Baltimore) (2016) 0.75
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2005) 11.91
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest (2014) 3.10
alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One (2010) 2.94
Common variants of the novel type 2 diabetes genes CDKAL1 and HHEX/IDE are associated with decreased pancreatic beta-cell function. Diabetes (2007) 2.73
Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care (2005) 2.53
Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology (2007) 2.50
Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans. Diabetes (2010) 2.44
Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension (2004) 2.33
Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes (2011) 2.21
Thyroid disorders in chronic hepatitis C. Am J Med (2004) 2.19
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia (2015) 2.13
Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes (2002) 2.06
Physical activity and insulin sensitivity: the RISC study. Diabetes (2008) 2.03
Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab (2006) 1.98
Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes (2007) 1.96
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol (2007) 1.92
Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol (2011) 1.89
Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care (2005) 1.83
Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab (2002) 1.73
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology (2009) 1.71
Meal and oral glucose tests for assessment of beta -cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab (2002) 1.71
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab (2010) 1.68
Quantification of liver glucose metabolism by positron emission tomography: validation study in pigs. Gastroenterology (2006) 1.66
Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab (2011) 1.63
Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects. Eur Heart J (2007) 1.63
Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab (2003) 1.61
Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Hum Mol Genet (2009) 1.61
Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care (2007) 1.57
Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care (2013) 1.56
Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2008) 1.53
Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes (2002) 1.51
IN PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM WHILE IN THERAPY WITH TABLET L-T4, THE LIQUID L-T4 FORMULATION IS MORE EFFECTIVE IN RESTORING EUTHYROIDISM. Endocr Pract (2016) 1.44
Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab (2006) 1.44
Pattern of expression of inflammatory markers in adipose tissue of untreated hypertensive patients. J Hypertens (2010) 1.43
Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids. Diabetes (2013) 1.41
Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab (2006) 1.41
Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care (2007) 1.32
Obesity and type 2 diabetes: what can be unified and what needs to be individualized? Diabetes Care (2011) 1.31
Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab (2009) 1.30
Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto's thyroiditis. J Clin Endocrinol Metab (2006) 1.29
Early hypertension is associated with reduced regional cardiac function, insulin resistance, epicardial, and visceral fat. Hypertension (2008) 1.27
Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes (2006) 1.25
Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. Diabetes (2013) 1.25
Thyroid disorders in chronic hepatitis C virus infection. Thyroid (2006) 1.21
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis. J Clin Endocrinol Metab (2004) 1.16
Prevalence of hypothyroidism and Graves disease in sarcoidosis. Chest (2006) 1.15
Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab (2002) 1.15
Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors. Diabetes Care (2008) 1.14
Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes (2011) 1.13
Fatty acid metabolism in the liver, measured by positron emission tomography, is increased in obese individuals. Gastroenterology (2010) 1.13
Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. Stroke (2007) 1.12
Increased fat mass compensates for insulin resistance in abdominal obesity and type 2 diabetes: a positron-emitting tomography study. Diabetes (2005) 1.11
High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab (2004) 1.11
Effect of acute hyperglycemia on insulin secretion in humans. Diabetes (2002) 1.10
A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol (2003) 1.09
Long-term effects of bariatric surgery on meal disposal and β-cell function in diabetic and nondiabetic patients. Diabetes (2013) 1.09
Differential effect of weight loss on insulin resistance in surgically treated obese patients. Am J Med (2005) 1.08
Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed Pharmacother (2008) 1.08
Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab (2005) 1.07
Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care (2010) 1.06
Genetic variants associated with glycine metabolism and their role in insulin sensitivity and type 2 diabetes. Diabetes (2013) 1.06
Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab (2012) 1.05
Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab (2006) 1.05
Erythrocyte sedimentation rate, coronary atherosclerosis, and cardiac mortality. Eur Heart J (2003) 1.05
Improvement in insulin sensitivity and β-cell function following ileal interposition with sleeve gastrectomy in type 2 diabetic patients: potential mechanisms. J Gastrointest Surg (2011) 1.05
Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology (2012) 1.05
Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms. Am J Physiol Endocrinol Metab (2009) 1.05
Carotid intima-media thickness in confirmed prehypertensive subjects: predictors and progression. Arterioscler Thromb Vasc Biol (2007) 1.04
Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care (2004) 1.03
beta-cell function in morbidly obese subjects during free living: long-term effects of weight loss. Diabetes (2005) 1.03
Sodium-glucose transporter-2 inhibition as an antidiabetic therapy. Nephrol Dial Transplant (2010) 1.02
Cytokines and HCV-related disorders. Clin Dev Immunol (2012) 1.02
Muscle metabolism and exercise tolerance in subclinical hypothyroidism: a controlled trial of levothyroxine. J Clin Endocrinol Metab (2005) 1.02
Redefining the diagnosis of diabetes using glycated hemoglobin. Diabetes Care (2009) 1.00
Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes (2002) 1.00
Thyroid cancer in systemic lupus erythematosus: a case-control study. J Clin Endocrinol Metab (2009) 1.00
The administration of L-thyroxine as soft gel capsule or liquid solution. Expert Opin Drug Deliv (2014) 1.00
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia (2014) 1.00